Ma et al [20] reported that the RR and DCR were 81% and 95% respectively in 21 NSCLC patients (EGFR non-selected) with BM treated by concurrent WBRT and gefitinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.